Physician profile
Ned R Warner
NPI 1235175027
$6,795.85
in general payments reported to CMS, 2019-2025
37 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $537 · 2021: $1,099 · 2022: $1,164 · 2023: $1,217 · 2024: $901 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,332.82 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $733.34 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $448.60 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.69 | 2019-2022 | |
| Gilead Sciences, INC. | $278.31 | 2019-2025 | |
| Braintree Laboratories, INC. | $254.19 | 2019-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $218.05 | 2022-2025 | Dupixent |
| Genzyme Corporation | $203.70 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $164.90 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $144.43 | 2019-2025 | |
| Ardelyx, INC. | $131.07 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $128.22 | 2022-2025 | Sucraid |
| Janssen Biotech, INC. | $121.28 | 2021-2025 | Tremfya |
| Pfizer INC. | $120.67 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $119.89 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $97.62 | 2020-2022 | |
| Alfasigma USA, INC. | $94.04 | 2020 | |
| Allergan, INC. | $87.30 | 2019 | |
| Medtronic, INC. | $80.37 | 2021-2024 | Endoflip |
| Merck Sharp & Dohme LLC | $74.71 | 2021-2023 | Dificid |
| Redhill Biopharma INC. | $63.62 | 2020-2021 | |
| Daiichi Sankyo INC. | $59.75 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $57.01 | 2025 | Vowst, Zenpep |
| Boston Scientific Corporation | $52.69 | 2019-2025 | Overstitch Nxt Endoscopic Suturing System |
| Madrigal Pharmaceuticals | $52.36 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $50.45 | 2023-2024 | Idacio |
| Pentax of America, INC. | $49.27 | 2023 | C2 Cryoballoon |
| Shield Therapeutics INC | $44.04 | 2024 | |
| Shire North American Group INC | $41.27 | 2019 | |
| Meridian Bioscience INC. | $35.47 | 2024 | |
| Amgen INC. | $27.11 | 2020-2023 | |
| Celltrion USA INC. | $25.94 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $24.53 | 2025 | Bylvay |
| Organon LLC | $15.71 | 2024 | |
| Biocon Biologics INC | $15.43 | 2025 | Yesintek |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.